Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00681889 · ClinicalTrials.gov registry record · Phase 1
Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)
A Phase 1 study, sponsored by Reza Dana, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00681889 is a Phase 1 study that has completed, run by Reza Dana, MD. The registered enrollment target is 9 participants.
The verdict
NCT00681889, a Phase 1 study, has completed, sponsored by Reza Dana, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effectiveness and safety of ranibizumab (Lucentis) in treatment of corneal neovascularization.
Interventions
- DRUG Ranibizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2008-04 |
| Est. Completion | 2010-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00681889
The ClinicalTrials.gov registry entry for NCT00681889 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Reza Dana, MD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ranibizumab is the first listed.
NCT00681889 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00681889 about?
NCT00681889 is a clinical study titled "Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)". The purpose of this study is to determine the effectiveness and safety of ranibizumab (Lucentis) in treatment of corneal neovascularization.
What is the current status of trial NCT00681889?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2008-04. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00681889?
The interventions under investigation include: Ranibizumab (DRUG).
Who is sponsoring clinical trial NCT00681889?
This trial is sponsored by Reza Dana, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.